Praxis Precision Medicines, Inc.
elsunersen
early-seizure-onset SCN2A DEE
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for elsunersen in early-seizure-onset SCN2A DEE are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The EMBRAVE Part A Phase 1/2 study evaluating SCN2A early seizure onset patients with a 3:1 drug to sham arm evaluating safety and seizure reduction is on track for topline results in the first half of 2026.”